Another PROTAC entered clinical study
Posted Mar 30
December 24, 2021—Accutar Biotechnology, a biotechnology company focused on AI drug development, announced that the FDA has approved its IND for AC0176 for the treatment of patients with metastatic decompensated refractory prostate cancer (mCRPC).
AC0176 ...